These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
76 related articles for article (PubMed ID: 25075016)
1. Random migration contributes to cytotoxicity of activated CD8+ T-lymphocytes but not NK cells. Onishi H; Kiyota A; Koya N; Tanaka H; Umebayashi M; Katano M; Morisaki T Anticancer Res; 2014 Aug; 34(8):3947-56. PubMed ID: 25075016 [TBL] [Abstract][Full Text] [Related]
2. Heterotypic interaction of CRTAM with Necl2 induces cell adhesion on activated NK cells and CD8+ T cells. Arase N; Takeuchi A; Unno M; Hirano S; Yokosuka T; Arase H; Saito T Int Immunol; 2005 Sep; 17(9):1227-37. PubMed ID: 16091383 [TBL] [Abstract][Full Text] [Related]
3. Canine CD8 T cells showing NK cytotoxic activity express mRNAs for NK cell-associated surface molecules. Lin YC; Huang YC; Wang YS; Juang RH; Liao KW; Chu RM Vet Immunol Immunopathol; 2010 Feb; 133(2-4):144-53. PubMed ID: 19709755 [TBL] [Abstract][Full Text] [Related]
4. Establishment, characterization, and successful adaptive therapy against human tumors of NKG cell, a new human NK cell line. Cheng M; Ma J; Chen Y; Zhang J; Zhao W; Zhang J; Wei H; Ling B; Sun R; Tian Z Cell Transplant; 2011; 20(11-12):1731-46. PubMed ID: 21669033 [TBL] [Abstract][Full Text] [Related]
6. Expression and function of LFA-1 on A-NK and T-LAK cells: role in tumor target killing and migration into tumor tissue. Donskov F; Basse PH; Hokland M Nat Immun; 1996-1997; 15(2-3):134-46. PubMed ID: 9162263 [TBL] [Abstract][Full Text] [Related]
7. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study. Chan JK; Hamilton CA; Cheung MK; Karimi M; Baker J; Gall JM; Schulz S; Thorne SH; Teng NN; Contag CH; Lum LG; Negrin RS Clin Cancer Res; 2006 Mar; 12(6):1859-67. PubMed ID: 16551871 [TBL] [Abstract][Full Text] [Related]
8. Rapid killing of murine lymph node T blasts by intestinal intraepithelial lymphocytes in vitro. Kawamoto Y; Sasaki K; Kato Y; Kojima K; Tsuji T; Miyama A Eur J Immunol; 1996 Mar; 26(3):653-8. PubMed ID: 8605934 [TBL] [Abstract][Full Text] [Related]
10. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells. Matusali G; Tchidjou HK; Pontrelli G; Bernardi S; D'Ettorre G; Vullo V; Buonomini AR; Andreoni M; Santoni A; Cerboni C; Doria M FASEB J; 2013 Jun; 27(6):2440-50. PubMed ID: 23395909 [TBL] [Abstract][Full Text] [Related]
11. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 2. The role of non-activated and rIL-2-activated CD4+ and CD8+ T cells in immunotherapy for leukemia. Weiss L; Reich S; Slavin S Cytokines Cell Mol Ther; 1999 Sep; 5(3):153-8. PubMed ID: 10641573 [TBL] [Abstract][Full Text] [Related]
12. The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. Lanier LL; Le AM; Civin CI; Loken MR; Phillips JH J Immunol; 1986 Jun; 136(12):4480-6. PubMed ID: 3086432 [TBL] [Abstract][Full Text] [Related]
13. Activated allogeneic NK cells as suppressors of alloreactive responses. Hu B; He Y; Wu Y; Bao G; Liu H; Welniak LA; Murphy WJ Biol Blood Marrow Transplant; 2010 Jun; 16(6):772-81. PubMed ID: 20197103 [TBL] [Abstract][Full Text] [Related]
14. Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3. Scheffold C; Kornacker M; Scheffold YC; Contag CH; Negrin RS Cancer Res; 2002 Oct; 62(20):5785-91. PubMed ID: 12384539 [TBL] [Abstract][Full Text] [Related]
15. CD8-interaction mutant HLA-Cw3 molecules protect porcine cells from human natural killer cell-mediated antibody-dependent cellular cytotoxicity without stimulating cytotoxic T lymphocytes. Sharland A; Lee JH; Saidman S; Waneck GL Transplantation; 2003 Dec; 76(11):1615-22. PubMed ID: 14702534 [TBL] [Abstract][Full Text] [Related]
16. Ex vivo expansion of non-MHC-restricted cytotoxic effector cells as adoptive immunotherapy for myeloma. Wu JY; Ernstoff MS; Hill JM; Cole B; Meehan KR Cytotherapy; 2006; 8(2):141-8. PubMed ID: 16698687 [TBL] [Abstract][Full Text] [Related]
17. Characterization of cord blood natural killer and lymphokine activated killer lymphocytes following ex vivo cellular engineering. Ayello J; van de Ven C; Fortino W; Wade-Harris C; Satwani P; Baxi L; Simpson LL; Sanger W; Pickering D; Kurtzberg J; Cairo MS Biol Blood Marrow Transplant; 2006 Jun; 12(6):608-22. PubMed ID: 16737934 [TBL] [Abstract][Full Text] [Related]
18. Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells. Roda JM; Parihar R; Magro C; Nuovo GJ; Tridandapani S; Carson WE Cancer Res; 2006 Jan; 66(1):517-26. PubMed ID: 16397268 [TBL] [Abstract][Full Text] [Related]
19. Activated T cells inhibit NK cell-mediated tumour rejection. Wang XJ; Hu J; Yuan J; Peng YM; Gui L; He WF; Tan J; Luo GX; Wu J Scand J Immunol; 2009 Apr; 69(4):337-41. PubMed ID: 19284498 [TBL] [Abstract][Full Text] [Related]
20. Generation propagation, and targeting of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus recombinant IL-2. An efficient strategy for adoptive tumor immunotherapy. Nishimura T; Nakamura Y; Takeuchi Y; Tokuda Y; Iwasawa M; Kawasaki A; Okumura K; Habu S J Immunol; 1992 Jan; 148(1):285-91. PubMed ID: 1345787 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]